Novocure stock tumbles after trial misses primary endpoint

NVIDIA (NVDA) is mentioned only in market context within an article about Novocure’s trial failure. Novocure shares fell 10% after its Phase 3 TRIDENT study missed the primary endpoint, failing to show a statistically significant overall survival benefit for newly diagnosed glioblastoma patients when Tumor Treating Fields therapy was started earlier. The result is negative for Novocure and its commercial outlook, but it does not indicate a direct catalyst for NVIDIA. The article also includes a broader market snapshot showing tech stocks, including NVDA, trading lower on the day.